Movement Disorders

The deputy director at Association of Movement Disorder Advanced Practice Providers (AMDAPP) recapped key themes in movement disorders presented at the 2026 AMDAPP conference. [WATCH TIME: 5 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 24, 2026.

A recent study suggested that probiotic regimens and biomarker-guided strategies may be a promising signal for reducing excessive daytime sleepiness in patients with PD and CKD.

New findings from a post hoc analysis of 2 phase 3 trials, presented at AAN 2026, reported that a majority of participants with advanced Parkinson disease had no troublesome dyskinesia at follow-up.

The president at Cala Health discussed the clinical role, evidence base, and future potential of the Cala kIQ Plus wearable TAPS therapy for patients with essential tremor and Parkinson disease at AAN 2026.

The associate professor of neurology at Mayo Clinic Rochester discussed why earlier detection of environmental risk in Parkinson disease remains difficult and how gene-environment research may help move the field forward. [WATCH TIME: 4 minutes]

Real-world data of the ELEVATE-PD study, presented at AAN 2026, suggest that switching to IPX203 from other levodopa-based therapies may improve motor function in patients with Parkinson disease.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 17, 2026.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Julie Kurek, MD. [LISTEN TIME: 25 minutes]

The FDA has cleared an updated Cala kIQ Plus wearable system, adding adaptive features to support personalized management of hand tremor in essential tremor and Parkinson disease.

The director of neurointerventional surgery at Abbott Northwestern Hospital, part of Allina Health, discussed evolving stroke care, patient selection, and emerging neurointerventional technologies shaping clinical practice.

The senior vice president of clinical development for Lundbeck discusses the mechanism and early clinical promise of Lu AF28996, an oral dual D1/D2 agonist for advanced Parkinson disease. [WATCH TIME: 3 minutes]

A data-driven slideshow for National Public Health Week highlights the global burden of neurologic diseases, featuring key statistics on prevalence, disability, and workforce gaps across major conditions.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 10, 2026.

Steven Markos, MD, a physician at Hackensack Meridian JFK Johnson Rehabilitation Institute, discussed a two-week inpatient rehabilitation program and its impact on functional and speech outcomes in Parkinson disease.

The professor of neurology at Mayo Clinic spoke about the current state of biomarker research in MSA. [WATCH TIME: 8 minutes]

In a preclinical study, subthalamic nucleus (STN) low-beta power negatively correlated with wake quantity, whereas STN and motor cortex high-beta power demonstrated a positive correlation with wakefulness.

Jonathan Charlesworth, PhD, chief scientific officer at Noctrix Health, discusses emerging research connecting restless legs syndrome with neurologic conditions such as multiple sclerosis, and the role of the FDA-cleared Nidra wearable device in patient care.

New data from the pivotal study of investigational therapy zilganersen in Alexander disease will be presented at the 2026 American Academy of Neurology (AAN) annual meeting in Chicago.

A new retrospective analysis presented at AD/PD 2026 showed that cutaneous phosphorylated α-synuclein testing reduced diagnostic and management-related health care expenditures.

Levacetylleucine met its primary end point in a phase 3 trial of patients living with ataxia-telangiectasia, with no drug-related serious adverse events reported, supporting the sNDA.

An analysis of baseline data from the phase 2b LUMA study suggested that keystroke dynamics captured through a smartphone-based typing task could provide a reliable method for assessing disease progression in Parkinson disease.

Early ASPIRO trial data show autologous stem-cell dopamine precursors stay safe at 12 months, with improved PD motor scores and PET-confirmed grafting.

UK platform trial enrolls 1,600 with Parkinson’s to rapidly test telmisartan, terazosin and new candidates via shared placebo and virtual visits.

A global survey of neurologists and psychiatrists found that although tetrabenazine remains widely used for tardive dyskinesia and Huntington disease–related chorea, side effects frequently prevent optimal dose titration and lead to treatment discontinuation.